Global Antipsychotic Drugs Market - 2025-2032

The global antipsychotic drugs market reached US$ 16.41 billion in 2024 and is expected to reach US$ 32.83 billion by 2032, growing at a CAGR of 7.9% during the forecast period 2025-2032.

Antipsychotic medications are an important class of psychiatric drugs prescribed to manage psychosis, which includes symptoms such as delusions, hallucinations, and disorganized thinking. These medications are primarily used to treat conditions like schizophrenia, bipolar disorder, and severe depression.

Antipsychotics can be administered in various forms. The most common method is oral ingestion through tablets or liquid formulations. Additionally, some antipsychotics are available as depot injections, which provide a slow-release, long-acting treatment option given every few weeks.

Antipsychotics are effective in alleviating psychotic symptoms and stabilizing mood and help individuals manage their symptoms more effectively, allowing for improved functioning in daily life. The ongoing development of these medications continues to enhance their efficacy and safety profiles, making them a vital component of modern psychiatric care. For instance,

Market Dynamics: Drivers & Restraints

Introduction of innovative antipsychotic drugs

The introduction of innovative antipsychotic drugs is expected to significantly propel the antipsychotic drugs market due to several compelling reasons. Companies are introducing innovative solutions with the ability to treat multiple mental health disorders. For instance, in April 2023, Teva and MedinCell announced FDA approval of UZEDY (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia in adults. Advanced medications, particularly second and third-generation antipsychotics, are designed with enhanced tolerability, which is crucial for ensuring patient adherence to treatment regimens and consequently increasing the overall demand for these drugs.

Additionally, advancements in pharmaceutical research and development have led to innovative formulations and delivery methods, such as long-acting injectables that provide sustained therapeutic effects while reducing the frequency of dosing. Such innovations not only improve patient compliance but also expand treatment options for complex mental health disorders. For instance, in September 2024, Bristol Myers Squibb received the U.S. Food and Drug Administration (FDA) approval for COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M 1 and M 4 receptors in the brain without blocking D2 receptors.

Furthermore, the growing global awareness of mental health issues has accelerated the demand for effective antipsychotic treatments, as more individuals seek help for conditions like schizophrenia and bipolar disorder. As the market evolves, the emergence of targeted therapies that focus on specific neurotransmitter systems is also anticipated to attract significant interest from both clinicians and patients, reinforcing the market's growth trajectory.

Lack of awareness of mental health conditions

The lack of awareness regarding mental health conditions is anticipated to significantly impede the growth of the antipsychotic drugs market. Many individuals suffering from psychiatric disorders, such as schizophrenia and bipolar disorder, often do not recognize their symptoms or understand the critical importance of seeking treatment. This gap in awareness can lead to underdiagnosis and undertreatment, resulting in a smaller patient population that requires antipsychotic therapies. Consequently, pharmaceutical companies may struggle to expand their market reach and drive sales effectively.

Segment Analysis

The global antipsychotic drugs market is segmented based on drug type, indication, route of administration, distribution channel, end-user, and region.

Type:

Second-generation antipsychotic drugs segment is expected to dominate the global antipsychotic drugs market share

The second-generation antipsychotic drugs (SGAs) segment is poised to maintain its dominant position in the antipsychotic drugs market, primarily due to their enhanced safety profiles and greater efficacy compared to first-generation antipsychotics (FGAs). Second-generation antipsychotics (SGAs) are a newer class of antipsychotic medications used to treat schizophrenia, bipolar disorder, and related psychiatric conditions

The ongoing product launches and advancements in drug development are expected to further propel the growth of SGAs, with a notable increase in long-acting injectable formulations that improve patient adherence and treatment outcomes. For instance, in June 2021, Alkermes plc received the U.S. Food and Drug Administration (FDA) approval for LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

Thus, the above factors are expected to show a promising dominance of SGAs in the antipsychotic market in the future, supported by a shift towards innovative treatment options that prioritize both efficacy and safety for patients.

Geographical Analysis

North America is expected to hold a significant position in the global antipsychotic drugs market share

North America is expected to maintain a dominant position in the global antipsychotic drugs market. This dominance is driven by several key factors, including a high prevalence of psychiatric disorders such as schizophrenia and bipolar disorder, which affect millions of people in the region. For instance, according to the report by the National Alliance on Mental Illness (NAMI) in 2022, it indicates that an estimated 7 million adults in the U.S. live with bipolar disorder alone, highlighting the significant demand for effective antipsychotic treatments.

According to the National Institute of Mental Health, it is estimated that more than one in five U.S. adults live with a mental illness (59.3 million in 2022.

North America has a well-established healthcare infrastructure and a strong presence of leading biopharmaceutical companies that are continuously innovating and launching new products. For instance, in April 2024, Vanda Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of patients with schizophrenia.

North America's healthcare system supports extensive research and development initiatives aimed at creating safer and more effective antipsychotics, including long-acting injectable formulations that improve patient adherence to treatment.

Asia Pacific is growing at the fastest pace in the global antipsychotic drugs market

The Asia Pacific region is experiencing the fastest growth in the antipsychotic drugs market, driven by several key factors. One of the primary contributors is the high prevalence of mental health disorders, with millions affected by conditions such as depression and schizophrenia. For instance, WHO estimates that 54 million people in China suffer from depression, and about 41 million suffer from anxiety disorders. This highlights the urgent need for effective treatment options. Additionally, mental health issues are prevalent across the region, with studies showing that anywhere from 4% to 20% of adults in various countries experience diagnosable mental illnesses annually.

Competitive Landscape

The major global players in the antipsychotic drugs market include Dr. Reddy's Laboratories Ltd., Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Alkermes, Eli Lilly and Company, Bristol-Myers Squibb Company, Sumitomo Pharma Co., Ltd. and Pfizer Inc. among others.

Key Developments

• In December 2024, Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on central nervous system disorders, submitted a supplemental New Drug Application to the FDA seeking approval for Caplyta (lumateperone) as an additional treatment for Major Depressive Disorder (MDD) in adults.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Antipsychotic Drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.